Holen Sie sich die Stockscreener-App
1.19
5.56%
-0.07
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
Renaissance Technologies LLC Acquires 133,018 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology Inc (PYXS) is a good investment, but the stock may be overvalued - uspostnews.com
Taking a look at what insiders are doing to gauge the Pyxis Oncology Inc (PYXS)’s direction - knoxdaily.com
Pyxis Oncology reveals promising preclinical data for cancer drug - Investing.com
Pyxis Oncology reveals promising preclinical data for cancer drug By Investing.com - Investing.com UK
Pyxis Oncology Highlights Promising Preclinical Data for Micvotabart Pelidotin (MICVO) in Cancer Therapy at AACR 2025 - Nasdaq
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC - TradingView
Novel Cancer Drug Shows 91% Tumor Inhibition in Breakthrough Study | PYXS Stock News - Stock Titan
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Pyxis Oncology Inc (PYXS) requires closer examination - uspostnews.com
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms - Yahoo Finance
Pyxis Oncology Inc (PYXS) receives a Mkt perform rating from William Blair - knoxdaily.com
Pyxis Oncology Inc (PYXS) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Top Cancer Stocks to Buy to Boost Your Portfolio's Health - Yahoo Finance
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Sei Investments Co. Acquires New Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
American Century Companies Inc. Has $468,000 Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS) - marketscreener.com
Pyxis Oncology stock plunges to 52-week low of $0.86 - Investing.com Australia
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times
CEO Spotlight: Pyxis Oncology to Reveal Latest Cancer Drug Strategy at Elite Stifel Forum - Stock Titan
Pyxis Oncology stock hits 52-week low at $0.98 amid downturn - Investing.com Canada
Is it possible to buy Pyxis Oncology Inc(PYXS) shares at a good price now? - US Post News
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - The Manila Times
Pyxis Oncology to Present Preclinical Data for Micvo Cancer Drug Candidate - MarketScreener
Pyxis Oncology Highlights Strategic Focus on Lead Candidate - TipRanks
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Analysts Set Expectations for Pyxis Oncology Q1 Earnings - Defense World
HC Wainwright Expects Stronger Earnings for Pyxis Oncology - Defense World
Royal Bank of Canada Reiterates Outperform Rating for Pyxis Oncology (NASDAQ:PYXS) - Defense World
Optimistic Buy Rating for Pyxis Oncology Amid Strategic Focus and Promising Drug Developments - TipRanks
HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - Defense World
William Blair Weighs in on Pyxis Oncology FY2027 Earnings - Defense World
Pyxis Oncology’s (PYXS) Buy Rating Reaffirmed at HC Wainwright - The AM Reporter
Pyxis Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RBC Capital Remains a Buy on Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology Advances Cancer Therapeutics with MICVO - TipRanks
Jefferies cuts Pyxis Oncology target to $6, maintains Buy By Investing.com - Investing.com Australia
Jefferies cuts Pyxis Oncology target to $6, maintains Buy - Investing.com India
Pyxis Oncology Announces CMO Resignation and New Trials - TipRanks
Pyxis Oncology, Inc. SEC 10-K Report - TradingView
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Pyxis Oncology Reports Promising Phase 1 Data for MICVO in Head and Neck Cancer, Receives FDA Fast Track Designation - Nasdaq
Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms - Endpoints News
Pyxis Oncology Inc expected to post a loss of 33 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) to Release Earnings on Thursday - Defense World
Closing Figures Unveiled: Pyxis Oncology Inc (PYXS) Drop -2.80, Closes at 1.04 - The Dwinnex
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - The Manila Times
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):